Barclays
CTOR

Barclays’s Citius Oncology CTOR Stock Holding History

Barclays’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59 Buy
+90
New +$72 ﹤0.01% 5227

Other funds holding CTOR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's CTOR Position: Q2 2026 in Review

Barclays opened a new position in Citius Oncology (CTOR) in Q2 2026: 90 shares worth $59. The stake represents ﹤0.01% of the portfolio and ranks #5227 among its holdings.

19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • Barclays held 90 shares of Citius Oncology worth $59 as of Q2 2026.
  • Citius Oncology was a new Barclays position in Q2 2026.
  • Citius Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5227 holding.
  • 19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.